Clinical trials

Testing the safety and efficacy of STC-15, first-in-class METTL3 inhibitor

Study

Program: STC-15
Indications: NSCLC, HNSCC, Melanoma, Endometrial Cancer
Status: Phase 1b/2, recruiting patients

Trial overview

The Phase 1b/2 clinical trial (NCT06975293) is designed to evaluate the efficacy and safety of STC-15 in combination with toripalima-tpzi in non-small cell lung cancer, squamous cell carcinoma of the head and neck, melanoma, and endometrial cancer in up to 188 patients.

For more information, please visit clinicaltrials.gov.